Business Context and Reporting Period
This Form 8-K filing by iSpecimen Inc. (Nasdaq: ISPC) covers events occurring on May 8, 2026, with a report date of May 13, 2026. The Company is an emerging growth corporation incorporated in Delaware, headquartered in Woburn, MA. The filing primarily addresses a private placement of equity securities, the resolution of a Nasdaq listing compliance issue, and the status of the Company's 2025 Annual Meeting of Stockholders.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company closed a private placement on May 11, 2026, generating aggregate gross proceeds of approximately $2.5 million.
- Securities Issued: The offering consisted of 85,202 shares of Common Stock and 403,088 Pre-Funded Warrants.
- Pricing: Common Stock was sold at $5.12 per share. Pre-Funded Warrants were sold at $5.1199 per warrant (exercisable at $0.0001 per share).
- Use of Proceeds: Net proceeds are designated for working capital, including up to $900,000 allocated for marketing expenses.
- Dilution Cap: The total shares issuable to investors (including upon warrant exercise) are capped at 19.99% of outstanding Common Stock prior to the agreement, pending stockholder approval.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes and Corporate Events
- Equity Offering: The Company entered into a Securities Purchase Agreement with accredited investors to raise capital, utilizing a mix of direct stock sales and pre-funded warrants to manage beneficial ownership limits (4.99% threshold).
- Nasdaq Compliance: The Company previously received notice on November 19, 2025, regarding non-compliance with the $1.00 minimum bid price requirement. On May 12, 2026, Nasdaq confirmed the Company regained compliance as the closing bid price remained at or above $1.00 for 10 consecutive business days (April 28 to May 11, 2026).
- Annual Meeting Status: The 2025 Annual Meeting, originally scheduled for December 31, 2025, has been adjourned multiple times (January through May 2026) due to a lack of quorum. It is scheduled to reconvene on May 29, 2026.
Outlook, Risks, and Contingencies
- Registration Rights: The Company agreed to file a registration statement within 30 days of the closing to register the resale of the newly issued securities.
- Stockholder Approval: The 19.99% issuance cap is in effect until the Company obtains stockholder approval required under Nasdaq Listing Rules, which is pending the outcome of the reconvened Annual Meeting.
- Quorum Risk: The repeated failure to achieve a quorum for the Annual Meeting presents a risk to the timely approval of corporate governance proposals and the removal of the issuance cap.
Investor Verification Checklist
- Verify the final net proceeds after deducting placement agent fees and offering expenses.
- Confirm the outcome of the Annual Meeting reconvened on May 29, 2026, specifically regarding the approval of the equity issuance cap.
- Monitor the filing of the registration statement for the resale of the new securities within the 30-day window.
- Review the Company's cash burn rate and runway given the allocation of $900,000 for marketing expenses.